(Q24616434)

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

The role of interleukin-2 during homeostasis and activation of the immune system

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Interleukin-2 and regulatory T cells in graft-versus-host disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Immunotherapy of kidney cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Evidence that cervical cancer cells secrete IL-2, which becomes an autocrine growth factor

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Human melanoma cell line M14 secretes a functional interleukin 2.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3421468

Fluctuation of systemic immunity in melanoma and implications for timing of therapy

28 November 2018

1 reference

12 December 2020

Human melanoma cells express a functional interleukin-2 receptor

1 reference

12 December 2020

Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers

1 reference

12 December 2020

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

12 December 2020

Dendritic cell density and activation status of tumour-infiltrating lymphocytes in metastatic human melanoma: possible implications for sentinel node metastases

1 reference

12 December 2020

The dynamic human immune response to cancer: it might just be rocket science

1 reference

12 December 2020

A delicate balance: tweaking IL-2 immunotherapy

1 reference

12 December 2020

Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis

1 reference

12 December 2020

Mechanism of immune response during immunotherapy

1 reference

12 December 2020

Early kinetic window of target T cell susceptibility to CD25+ regulatory T cell activity

1 reference

12 December 2020

Identifiers

DOI

10.2147/CMAR.S33979

1 reference

release_prtvoudptndd3flv7zqe54ma7u

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/prtvoudptndd3flv7zqe54ma7u

24 November 2022

mapped directly with Wikidata item

1 reference

1 reference

PubMed publication ID

22904643

1 reference